Sources: 1BitterDB, 4ClinicalTrials, 10DGIdb, 14DrugBank, 16FDA, 29HMDB, 33IUPHAR, 35LifeMap Discovery®, 44NCI, 46NDF-RT, 50Novoseek, 56PharmGKB, 68UMLSSee all MalaCards sources |
FDA approved drugs:
| id |
|
Drug Name |
Active Ingredient(s)16 |
Company |
Approval Date |
| 1 |
|
Imbruvica16 44 |
IBRUTINIB |
Pharmacyclics |
November of 2013/ February 2014 |
Disease/s that Drug Treats:mantle cell lymphoma/chronic lymphocytic leukemia
Indications and Usage:16 IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with: Mantle cell lymphoma (MCL) who have received at least one priortherapy (1.1).Accelerated approval was granted for this indication based on overallresponse rate. Continued approval for this indication may be contingentupon verification of clinical benefit in confirmatory trials. Chronic lymphocytic leukemia (CLL) who have received at least oneprior therapy (1.2). Chronic lymphocytic leukemia with 17p deletion (1.3). Waldenströmâs macroglobulinemia (WM) (1.4).
DrugBank Targets:14 1. Tyrosine-protein kinase BTK
Mechanism of Action:16
Target: Bruton's tyrosine kinase (Btk)
Action: selective inhibitor
FDA: Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteineresidue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is asignaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTKâsrole in signaling through the B-cell surface receptors results in activation of pathways necessaryfor B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibitsmalignant B-cell proliferation and survival in vivo as well as cell migration and substrateadhesion in vitro.
|
| 2 |
|
Revlimid16 44 |
LENALIDOMIDE |
Celgene |
June 2013 |
Disease/s that Drug Treats:mantle cell lymphoma
Indications and Usage:16 REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4).
DrugBank Targets:14 1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2
Mechanism of Action:16
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
|
| 3 |
|
Velcade16 44 |
BORTEZOMIB |
Millennium Pharmaceuticals |
May 2003 |
Disease/s that Drug Treats:Multiple Myeloma
Indications and Usage:16 VELCADE is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma (1.1) treatment of patients with mantle cell lymphoma (1.2)
DrugBank Targets:14 1. 26S proteasome non-ATPase regulatory subunit 2;2. 26S proteasome non-ATPase regulatory subunit 1;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-5;5. Proteasome subunit beta type-2
Mechanism of Action:16
Target: 26S proteasome
Action: reversible inhibitor of chymotrypsin-like activity
FDA: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammaliancells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasomepathway plays an essential role in regulating the intracellular concentration of specific proteins,thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targetedproteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostaticmechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety ofcancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models,including multiple myeloma.
|
Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 492)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Etoposide | approved | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 1232 | 33419-42-0 | 36462 | (-)-Etoposide 121471-01-0 136598-18-0 201594-04-9 33419-42-0 35317-32-9 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside 51854-34-3 76576-58-4 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one AB00438905 AC1L1FN8 AC1L1VT3 AC1L6246 AC1NR4OG AC1O4WGG AC1O7M1N AC1Q47JJ Ambap33419-42-0 BPBio1_000673 BRD-K37798499-001-02-5 BSPBio_000611 Bio1_000489 Bio1_000978 Bio1_001467 C01576 CCRIS 2392 CHEBI:4911 CHEBI:588795 CHEMBL44657 CID11758093 CID284997 CID3310 CID36462 CID5284558 CID6419930 CID6610299 CPD000112002 D00125 DB00773 DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE, Demethyl Epipodophyllotoxin Ethylidine Glucoside Demethyl-epiodophyllotoxin ethylidene glucoside Demethylepipodophyllotoxin-beta-D-ethylideneglucoside E0675 E1383_SIGMA EINECS 251-509-1 EPE EPEG ETOP Epipodophyllotoxin Epipodophyllotoxin VP-16213 Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside) Eposide Eposin | Eposin, Vepesid, VP-16, Toposar, Etoposide Etopol Etopophos Etopophos (phosphate salt) Etoposid Etoposide Etoposide (JP15/USP/INN) Etoposide (VP16) Etoposide [USAN:INN:BAN:JAN] Etoposido Etoposido [INN-Spanish] Etoposidum Etoposidum [INN-Latin] Etosid HMS1569O13 HMS2052N05 HMS2089F14 HSDB 6517 I06-0248 KBioSS_002410 LS-1214 Lastet MLS000049957 MLS001074951 MLS001424283 MLS002153463 MLS002207239 MLS002222184 MolPort-003-983-431 MolPort-004-905-001 MolPort-004-955-161 NCGC00025056-02 NChemBio.2007.10-comp19 NK 171 NSC 141540 NSC-141540 NSC141540 Prestwick0_000396 Prestwick1_000396 Prestwick2_000396 Prestwick3_000396 Prestwick_211 S1225_Selleck SAM001246880 SMR000112002 SPBio_002532 ST056353 Toposar UNII-6PLQ3CP4P3 VP 16 VP 16 (pharmaceutical) VP 16-213 VP 16213 VP-16 VP-16-213 VePESID (TN) VePesid Vepesid Vepesid J Vepeside ZINC03830818 ZINC03938684 Zuyeyidal etoposide nchembio.573-comp8 nchembio873-comp2 trans-Etoposide |
| | 2 | | rituximab | approved | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 1654 | 174722-31-7 | 10201696 | AntiCD20 IDEC-102 IDEC-C2B8 | Ig gamma-1 chain C region MabThera Mabthera Rituxan rituximab |
| | 3 | | Doxorubicin | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1 | 1714 | 23214-92-8 | 31703 | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione 111266-55-8 14-Hydroxydaunomycin 14-Hydroxydaunorubicine 14-hydroxydaunomycin 14-hydroxydaunorubicine 23214-92-8 23257-17-2 24385-08-8 25311-50-6 25316-40-9 25316-40-9 (hydrochloride) 29042-30-6 AC1L1M5T AC1Q29OJ ADM ADR Adriablastin Adriacin (hydrochloride salt) Adriamycin Adriamycin PFS Adriamycin PFS (hydrochloride salt) Adriamycin RDF Adriamycin RDF (hydrochloride salt) Adriamycin Semiquinone Adriamycin semiquinone Adriblas tina Adriblastin Adriblastina Adriblastina (TN) Adriblastina (hydrochloride salt) Aerosolized Doxorubicin BPBio1_000502 BRD-K92093830-003-04-3 BSPBio_000456 BSPBio_001031 C01661 C27H29NO11 CCRIS 739 CHEBI:28748 CHEMBL179 CID31703 Caelyx Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74 Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120 D03899 DB00997 DM2 DOX-SL Doxil Doxo Doxorubicin Doxorubicin (USAN/INN) Doxorubicin HCl | Doxorubicin Hydrochloride Doxorubicin [USAN:INN:BAN] Doxorubicin citrate Doxorubicin hydrochloride (hydrochloride salt) Doxorubicin-P4/D10 Doxorubicin-P4/D10 conjugate Doxorubicin-hLL1 Doxorubicin-hLL1 conjugate Doxorubicina Doxorubicina [INN-Spanish] Doxorubicine Doxorubicine [INN-French] Doxorubicinum Doxorubicinum [INN-Latin] EINECS 245-495-6 FI 106 Farmablastina (hydrochloride salt) HMS2089H06 HSDB 3070 Hydroxydaunomycin hydrochlor ide (hydrochloride salt) Hydroxydaunomycin hydrochloride (hydrochloride salt) Hydroxydaunorubicin Hydroxydaunorubicin hydrochloride (hydrochloride salt) JT9100000 LMPK13050001 LS-1029 LS-165655 MLS000759533 Myocet NCI-C01514 NChemBio.2007.10-comp13 NDC 38242-874 NIOSH/JT9100000 NSC 123127 Prestwick0_000438 Prestwick1_000438 Prestwick2_000438 Prestwick3_000438 Probes1_000151 Probes2_000129 RDF Rubex Resmycin Rubex Rubex (hydrochloride salt) SMP1_000106 SPBio_002395 TLC D-99 ThermoDox Triferric doxorubicin UNII-80168379AG adiblastine (hydrochloride salt) adr iablatina (hydrochloride salt) adriablastine (hydrochloride salt) adriablatina (hydrochloride salt) adriblatina (hydrochloride salt) doxorubicin nchembio809-comp5 |
| | 4 | | Cisplatin | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 2690 | 15663-27-1 | 84093, 441203, 2767 | (SP-4-1)-diamminedichloridoplatinum (SP-4-1)-diamminedichloroplatinum (SP-4-2)-diamminedichloridoplatinum (SP-4-2)-diamminedichloroplatinum Abiplatin Biocisplatinum Briplatin CACP CDDP CHEBI:35852 CID441203 CPD0-1392 CPDC CPDD Carboquone Cis Pt II Cis-DDP Cis-Diaminedichloroplatinum Cis-Diamminedichloroplatinum Cismaplat Cisplatine Cisplatino Cisplatinum Cisplatyl Citoplationo DB00515 DDP DDPT Diamminedichloroplatinum | EU-0100918 Lederplatin Neoplatin Peyrone's chloride Peyrone's salt Plastin Platamine Platiblastin Platidiam Platinex Platinol Platinol-AQ Platinoxan Platinum Ammine Chloride Platinum Ammonium Chloride Platinum Diamine Dichloride Randa Trans-DDP Trans-Diaminedichloroplatinum Trans-Diamminedichloroplatinum Trans-Dichlorodiammine Platinum Trans-Platinumdiammine Dichloride cis-DDP cis-Diamminedichloroplatinum cis-Dichlorodiammineplatinum(II) cis-[PtCl2(NH3)2] cis-diamminedichloridoplatinum(II) cis-diamminedichloroplatinum(II) nchembio773-comp1 trans-diamminedichloridoplatinum(II) | |
| | 5 | | Dexamethasone | approved, investigational, vet_approved | Phase 4, Phase 3, Phase 1, Phase 2 | 2084 | 50-02-2 | 5743 | (3H)-Dexamethasone .delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol .gamma.corten 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone 1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone 1-Dehydro-16α-methyl-9α-fluorohydrocortisone 137098-19-2 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone 16-alpha-Methyl-9-alpha-fluoroprednisolone 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol 16.alpha.-Methyl-9.alpha.-fluoroprednisolone 16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol 16alpha -Methyl-9alpha -fluoroprednisolone 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone 16alpha-Methyl-9alpha-fluoroprednisolone 16α-Methyl-9α-fluoro-1-dehydrocortisol 23495-06-9 31375_FLUKA 46165_FLUKA 46165_RIEDEL 50-02-2 8054-59-9 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione 9-Fluoro-16-methylprednisolone 9-alpha-Fluoro-16-alpha-methylprednisolone 9.alpha.-Fluoro-16.alpha.-methylprednisolone 906422-84-2 9A-FLUORO-16BETA-METHYLPREDNISOLONE 9alpha -Fluoro-16alpha -methylprednisolone 9alpha-Fluoro-16alpha-methylprednisolone 9alpha-fluoro-16alpha-methyl-Prednisolone 9α-Fluoro-16α-methylprednisolone AC-11056 AC1L1L1H AC1Q29DM AI3-50934 Adexone Aeroseb-D Aeroseb-Dex Aeroseb-dex Ak Dex Oph Otic Soln 0.1% Alcon Brand of Dexamethasone Anaflogistico Aphtasolon Aphthasolone Apo-dexamethasone Auxiron Azimycin (veterinary) Azium Azium (Veterinary) Azium (veterinary) BIDD:ER0494 BIDD:PXR0060 BRD-K38775274-001-02-3 BRD-K38775274-001-06-4 BSPBio_000995 Bisu DS Bisu Ds C15643 C22H29FO5 CCRIS 7067 CHEBI:41879 CHEMBL384467 CID5743 CPD-10549 CPD001227192 Calonat Corson Corsone Cortisumman D00292 D003907 D1756_SIGMA D4902_SIGMA D6645_SIGMA D8893_SIGMA D9184_SIGMA DB01234 DEX DEXA DEXONE 0.5 DEXONE 0.75 DEXONE 1.5 DEXONE 4 DXM DXMS Decacort Decacortin Decaderm Decadron Decadron (TN) Decadron Tablets, Elixir Decadron, Dexamethasone Decadron-LA Decadron-La Decagel Decaject Decaject L.A. Decaject-L.A. Decalix Decameth Decasone Decaspray Dectancyl Dekacort Delta1-9alpha-Fluoro-16alpha-methylcortisol Deltafluorene Dergramin Deronil Desadrene Desametasone Desametasone [DCIT] Desametasone [Dcit] Desamethasone Desameton Deseronil Dex-Ide Dex-ide Dexa Dexa Mamallet Dexa mamallet Dexa-Cortidelt Dexa-Cortisyl Dexa-Mamallet Dexa-Scheroson Dexa-Sine Dexa-cortidelt Dexa-cortisyl Dexa-scheroson Dexa-sine Dexacen-4 Dexacidin Dexacort Dexacortal Dexacortin Dexadeltone Dexafarma Dexair Dexalona Dexaltin Dexametasona Dexametasona [INN-Spanish] Dexametasone | Dexameth Dexamethansone Dexamethasone Dexamethasone (JP15/USP/INN) Dexamethasone Acetate Dexamethasone Alcohol Dexamethasone Base Dexamethasone Intensol Dexamethasone Sodium Phosphate Dexamethasone [INN:BAN:JAN] Dexamethasone alcohol Dexamethasone base Dexamethasone intensol Dexamethasone-omega Dexamethasonum Dexamethasonum [INN-Latin] Dexamethazone Dexamonozon Dexapolcort Dexapos Dexaprol Dexason Dexasone Dexasone 0.5mg Dexasone 0.75mg Dexasone 4mg Dexasporin Dexinolon Dexinoral Dexone Dexone 0.5 Dexone 0.75 Dexone 1.5 Dexone 4 Dexonium Dexpak Dextelan Dezone Dinormon Dxms ECR Brand of Dexamethasone EINECS 200-003-9 FT-0080377 Fluormethylprednisolone Fluormone Fluorocort Fortecortin Foy Brand of Dexamethasone Gammacorten HL-dex HMS1792A17 HMS1990A17 HMS2089N13 HSDB 3053 Hexadecadrol Hexadrol Hexadrol Elixir Hexadrol Tablets Hexadrol elixir Hl-Dex Hl-dex I06-1196 ICN Brand of Dexamethasone IontoDex Isopto-Dex Isopto-dex LS-7300 Lokalison F Lokalison f Loverine Luxazone MK 125 MLS001055412 MLS001332507 MLS001332508 Maxidex Maxidex Ont 0.1% Maxidex Sus 0.1% Maxitrol Mediamethasone Merck Brand of Dexamethasone Merz Brand 1 of Dexamethasone Merz Brand 2 of Dexamethasone Methylfluorprednisolone Mexidex Millicorten MolMap_000018 MolPort-003-846-433 Mymethasone NCGC00091019-01 NCGC00091019-02 NCGC00091019-03 NCGC00091019-04 NCGC00091019-05 NCI60_003067 NSC 34521 NSC34521 Naquasone (veterinary) Neomycin and polymyxin b sulfates and dexamethasone Neomycin and polymyxin b sulphates and dexamethasone OTO-104 Ocu-Trol Ocu-trol Oradexon PHL-dexamethasone PMS-dexamethasone Pet Derm III Pet Derm Iii Pet derm III Pet-Derm Iii Pms Dexamethasone Elixir 0.5mg/5ml Policort Posurdex Prednisolon F Prednisolon f Prednisolone F Prednisolone f Prodex S1322_Selleck SAM002548948 SGCUT00126 SK-Dexamethasone SK-dexamethasone SMP1_000092 SMR000857119 SMR001227192 ST50307091 Sandoz dexamethasone Sk-Dexamethasone Spectrum5_002019 Spoloven Sunia Sol D Sunia sol D Superprednol TL8003317 Tobradex Tobramycin and dexamethasone Tresaderm (veterinary) Turbinaire UNII-7S5I7G3JQL Visumetazone WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1 ZINC03875332 alpha -Fluoro-16-alpha -methylcortisol delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol delta1-9alpha-Fluoro-16alpha-methylcortisol dexamethasone nchembio809-comp2 to_000038 |
| | 6 | | Cytarabine | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 1093 | 147-94-4 | 6253 | (beta-D-Arabinofuranosyl)cytosine (beta-D-arabinofuranosyl)cytosine 1-.beta.-D-arabinofuranosyl-cytosine 1-Arabinofuranosylcytosine 1-beta -D-Arabinofaranosylcytosine 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone 1-beta -D-Arabinofuranosylcytosine 1-beta-D-Arabinofaranosylcytosine 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone 1-beta-D-Arabinofuranosyl-Cytosine 1-beta-D-Arabinofuranosylcytosine 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside 1-beta-D-Arabinosyl-Cytosine 1-beta-D-Arabinosylcytosine 147-94-4 1beta -Arabinofuranasylcytosine 1beta -D-Arabinofuranosylcytosine 1beta -D-Arabinosylcytosine 1beta-Arabinofuranasylcytosine 1beta-D-Arabinofuranosylcytosine 1beta-D-Arabinosylcytosine 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS] 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl 30399_FLUKA 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech] 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech] 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one 69-74-9 (hydrochloride) AC-1075 AC1L1M4F AC1Q52OJ AI3-52329 AR3 Alexan Ara-C Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine Ara-Cytidine AraC Arabinocytidine Arabinofuranosyl Cytidine Arabinofuranosylcytosine Arabinosyl Cytosine Arabinosylcytosine Arabitin Aracytidine Aracytin Aracytine Arafcyt BIDD:GT0371 BIDD:PXR0139 BTB15125 Beta-cytosine arabinoside C02961 C1768_SIGMA C2035 C9H13N3O5 CCRIS 913 CHEBI:28680 CHEMBL803 CHX 3311 CID6253 CPD000449317 CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9) Citarabina Citarabina [INN-Spanish] Cytarabin Cytarabina Cytarabine Cytarabine (JP15/USP/INN) | Cytarabine [USAN:INN:BAN:JAN] Cytarabine liposome injection Cytarabinoside Cytarabinum Cytarabinum [INN-Latin] Cytarbel Cytonal Cytosar Cytosar-U Cytosine 1-beta-D-arabinofuranoside Cytosine arabinofuranoside Cytosine arabinose Cytosine arabinoside Cytosine arabinoside (VAN) Cytosine beta-D-arabinofuranoside Cytosine beta-D-arabinofuranoside hydrochloride Cytosine beta-D-arabinoside Cytosine, beta -D-arabinoside Cytosine, beta-D-arabinoside Cytosine-1-beta-D-arabinofuranoside Cytosine-1-beta-D-arabinofuranoside hydrochloride Cytosine-beta -D-arabinofuranoside Cytosine-beta -arabinoside Cytosine-beta-D-arabinofuranoside Cytosine-beta-arabinoside Cytosinearabinoside D00168 DB00987 DepoCyte Depocyt Depocyt (TN) Depocyt (liposomal) Depocyte EINECS 205-705-9 Erpalfa FT-0082880 HMS2051K19 HMS2090A18 HSDB 3049 Intrathecal (injected into the spinal fluid) DepoCyt Intrathecal cytarabine (also known as ara-C) Iretin LS-860 Lopac0_000316 MLS000758310 MLS001066340 MolPort-001-792-509 NCGC00093356-03 NCGC00093356-04 NCGC00093356-05 NCI-C04728 NSC 287459 NSC287459 S1648_Selleck SAM001247012 SMR000449317 SR-01000075773-3 Spongocytidine TL8001048 Tarabine U 19920A U-19,920 U-19920 UNII-04079A1RDZ Udicil ZINC03795098 beta -D-arabinosylcytosine beta -arabinosylcytosine beta -cytosine arabinoside beta-Ara C beta-Ara c beta-Arabinosylcytosine beta-Cytosine arabinoside beta-D-Arabinosylcytosine cytarabine cytarabine liposome injection cytosine-β-D-arabinofuranoside |
| | 7 | | Vincristine | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1 | 904 | 2068-78-2, 57-22-7 | 5978 | 22-Oxovincaleukoblastin 22-Oxovincaleukoblastine 28379-27-3 57-22-7 AC1L1LJC C07204 C46H56N4O10 CCRIS 5763 CHEBI:28445 CID5978 D08679 DB00541 EINECS 200-318-1 HMS2090E19 HSDB 3199 Indole alkaloid LCR LS-228 Leurocristine Lilly 37231 (1:1 sulfate salt) Liposomal Vincristine Marqibo NCGC00163700-01 NCI-C04864 NCI60_026703 NSC-67574 Onco TCS | Oncovin Oncovin (1:1 sulfate salt) Oncovine Tecnocris Tecnocris (TN) UNII-5J49Q6B70F VCR VIN Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine Vincasar Vincasar (1:1 sulfate salt) Vincasar PFS Vincrex Vincrex (1:1 sulfate salt) Vincristin Vincristina Vincristina [DCIT] Vincristine (INN) Vincristine Sulfate Vincristine Sulfate PFS Vincristine [INN:BAN] Vincristinum Vincristinum [INN-Latin] Vincrstine Vincrystine Vinkristin Z-D-Val-Lys(Z)-OH vincristine | |
| | 8 | | Prednisone | approved, vet_approved | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 1359 | 53-03-2 | 5865 | (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione .delta. E .delta.(sup1)-Cortisone .delta.-Cortelan .delta.-Cortisone .delta.-Cortone .delta.-E .delta.1-Cortisone .delta.1-Dehydrocortisone .delta.sone 1,2-Dehydrocortisone 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione 1-Cortisone 1-Dehydrocortisone 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione 53-03-2 68-59-7 81552_FLUKA AC-11112 AC1L1LB2 AC1Q29EZ ACon0_000082 ACon1_000297 AI3-52939 Adasone Ancortone Apo-Prednisone Apo-prednisone BPBio1_000323 BRD-K85883481-001-04-2 BSPBio_000293 Betapar Bicortone Bio-0649 C07370 C21H26O5 CCRIS 2646 CHEBI:8382 CHEMBL635 CID5865 CPD001227202 Cartancyl Colisone Cortan Cortancyl Cortidelt Cotone DB00635 Dacorten Dacortin Decortancyl Decortin Decortisyl Dehydrocortisone Dekortin Delcortin Dellacort Dellacort A Delta Cortelan Delta E Delta E. Delta-Cortelan Delta-Dome Delta-cortelan Delta-cortisone Delta-cortone Delta-dome Deltacortene Deltacortisone Deltacortone Deltasone Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone Deltison Deltisona Deltisone Deltra Di-Adreson Diadreson EINECS 200-160-3 Econosone Encorton Encortone Enkortolon Enkorton Fernisone Fiasone HMS1568O15 HMS2090J13 HSDB 3168 Hostacortin In-Sone Incocortyl | Juvason Kortancyl LMST02030180 LS-1325 Liquid Pred Lisacort Lodotra MEGxm0_000443 MLS001061265 MLS001304073 MLS001335907 MLS001335908 MLS002154191 MLS002207083 Me-Korti Metacortandracin Meticorten Meticorten (Veterinary) Metrevet (Veterinary) MolPort-001-740-041 NCGC00090766-01 NCGC00090766-02 NCGC00090766-03 NCI-C04897 NCI60_000008 NSC 10023 NSC10023 Nisona Nizon Novoprednisone Nurison Orasone Origen Prednisone P1276 P6254_SIGMA PRD Panafcort Panasol Paracort Parmenison Pehacort Precort Predeltin Prednicen-M Prednicorm Prednicort Prednicot Prednidib Prednilonga Prednison Prednisona Prednisona [INN-Spanish] Prednisone Prednisone Intensol Prednisone [INN:BAN] Prednisonum Prednisonum [INN-Latin] Prednitone Prednizon Prednovister Presone Prestwick0_000077 Prestwick1_000077 Prestwick2_000077 Prestwick3_000077 Prestwick_405 Pronison Pronisone Rectodelt Retrocortine S1622_Selleck SAM002264641 SK-Prednisone SMR000718760 SMR001227202 SPBio_002214 Servisone Sone Sterapred Supercortil U 6020 UNII-VB0R961HZT Ultracorten Ultracortene WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ Winpred Wojtab ZINC03875357 Zenadrid Zenadrid (veterinary) Zenadrid [veterinary] delta cortelan delta(sup 1)-Cortisone delta(sup 1)-Dehydrocortisone delta-1-Cortisone delta-1-Dehydrocortisone delta-Cortisone delta-Cortone | |
| | 9 | | Miconazole | approved, investigational, vet_approved | Phase 4, Phase 3, Phase 2, Phase 1 | 3624 | 22916-47-8 | 4189 | (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole 1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole 1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole 22832-87-7 (NITRATE) 22916-47-8 75319-47-0 AB00053500 AC1L1HM1 AKOS001574474 Aflorix(nitrate) Albistat(nitrate) Andergin(nitrate) BPBio1_000279 BRD-A82396632-001-03-0 BRD-A82396632-008-02-7 BRN 0965511 BSPBio_000253 BSPBio_002033 CCRIS 7924 CHEBI:6923 CHEMBL91 CID4189 CPD-4501 Conofite(nitrate) D00416 DB01110 Dactarin Daktarin IV Daktarin iv DivK1c_000156 EINECS 245-324-5 Epi-Monistat(nitrate) Femizol-M Florid(nitrate) Gyno-Daktar(nitrate) HMS1568M15 HMS2090B21 I14-14342 IDI1_000156 Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI) KBio1_000156 KBio2_001445 KBio2_004013 KBio2_006581 KBio3_001533 KBioGR_000581 KBioSS_001445 LS-78378 Lotrimin AF(nitrate) MCZ MJR 1762 MLS002222203 Micantin (nitrate) Miconasil Nitrate | Miconazol Miconazol [INN-Spanish] Miconazole Miconazole (JP15/USP/INN) Miconazole 3 Miconazole 3 Combination Pack Miconazole 7 Combination Pack Miconazole [USAN:BAN:INN:JAN] Miconazole nitrate salt Miconazole-7 Miconazolo Miconazolo [DCIT] Miconazolum Miconazolum [INN-Latin] Micozole Minostate MolPort-002-557-553 Monazole 7 Monista (nitrate) Monistat Monistat (TN) Monistat 1 Combination Pack Monistat 3 Dual-Pak Monistat 3 Vaginal Ovules Monistat 5 Tampon Monistat 7 Dual-Pak Monistat 7 Vaginal Suppositories Monistat Dual- PAK Monistat IV Monistat iv (TN) Monistat iv (tn) Monistat-Derm NCI60_001353 NCI60_001380 NINDS_000156 NSC 170986 NSC169434 NSC170986 Novo-Miconazole Vaginal Ovules Oprea1_091955 Prestwick0_000067 Prestwick1_000067 Prestwick2_000067 Prestwick3_000067 Prestwick_335 R 18134 R-14,889 SMR001307249 SPBio_000976 SPBio_002174 STK834405 STOCK1S-93556 Spectrum2_001048 Spectrum3_000507 Spectrum4_000061 Spectrum5_001297 Spectrum_000965 UNII-7NNO0D7S5M Vusion Zimycan imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI) miconazole | |
| | 10 | | Cyclophosphamide | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 2829 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Anhydrous cyclophosphamide Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 | DB00531 DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide |
| | 11 | | Sirolimus | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1 | 1896 | 53123-88-9 | 5284616, 6436030, 46835353 | (-)-Rapamycin (-)-rapamycin 1fkb 1pbk 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone 53123-88-9 A422989, NSC226080 AC-722 AC1L1JH9 AC1L7MJ9 AC1L9ZMV AY 22989 AY-22989 AY22989 Ambotz53123-88-9 Antibiotic AY 22989 BIDD:PXR0165 Bio1_000293 Bio1_000782 Bio1_001271 Bio2_000375 Bio2_000855 BiomolKI2_000084 C07909 C51H79NO13 CBiol_002007 CCRIS 9024 CHEBI:100923 CHEBI:9168 CHEMBL413 CID10213190 CID10795871 CID11949238 CID11959112 CID313006 CID478951 CID5040 CID5284616 CID5358081 CID5374464 CID5460439 CID5497196 CID5924240 CID6436030 CID6610270 CID6610346 CID6711160 CID6713081 CID9833581 CID9854379 CID9854380 CID9962926 CID9962928 D00753 DB00877 DE-109 DivK1c_006936 | FT-0082351 HMS2089A21 HSDB 7284 KBio1_001880 KBio2_000410 KBio2_002978 KBio2_005546 KBio3_000779 KBio3_000780 KBioGR_000410 KBioSS_000410 LCP-Siro LMPK06000003 LS-143290 MLS000028373 MS-R001 MolMap_000043 MolPort-003-959-433 NCGC00021305-05 NCI60_001851 NCIMech_000355 NSC 226080 NSC226080 Perceiva QTL1_000069 R0395_SIAL R0395_SIGMA RAP RAPA RPM Rapammune Rapamune Rapamune (TN) Rapamycin Rapamycin (TN) Rapamycin C-7, analog 4 Rapamycin Immunosuppressant Drug Rapamycin from Streptomyces hygroscopicus S1039_Selleck SIIA 9268A SILA 9268A SILA9268A SMP1_000255 SMR000058564 Sirolimus Sirolimus (RAPAMUNE) Sirolimus (USAN/INN) Sirolimus [USAN:BAN:INN] Sirolimus, Rapamune,Rapamycin SpecPlus_000840 UNII-W36ZG6FT64 UNM-0000358684 WY-090217 Wy 090217 heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy nchembio.100-comp4 nchembio.2007.42-comp2 nchembio.79-comp1 nchembio762-comp1 nchembio883-comp3 rapamycin sirolimus |
| | 12 | | Lenograstim | approved | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 1202 | 135968-09-1 | | G-CSF (CHO cell derived) Glycosylated recombinant G-CSF Glycosylated recombinant granulocyte colony stimulating factor | Granulocyte colony stimulating factor 3 (CHO cell derived) Granulocyte colony-stimulating factor lenograstim Lenograstim (genetical recombination) Lenograstim rDNA | |
| | 13 | | Thiotepa | approved | Phase 4, Phase 2, Phase 3, Phase 1 | 216 | 52-24-4 | 5453 | | | 14 | | Everolimus | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 1896 | 159351-69-6 | 6442177 | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone (1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy 07741_FLUKA 159351-69-6 40-O-(2-hydroxyethyl)-rapamycin 42-O-(2-Hydroxyethyl)rapamycin Afinitor CERTICAN(R) CHEMBL1201755 Certican D02714 DB01590 | Everolimus Everolimus (JAN/USAN/INN) Everolimus [USAN] LS-143292 MolPort-003-847-342 MolPort-003-925-588 NCGC00167512-01 NVP-RAD-001 RAD 001 RAD-001 RAD-001C RAD001 RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus S1120_Selleck SDZ-RAD UNII-9HW64Q8G6G Zortress everolimus |
| | 15 | | Doxil | Approved June 1999 | Phase 4, Phase 3, Phase 2, Phase 1 | 1714 | | 31703 | | Evacet LipoDox Pegylated Liposomal Doxorubicin Hydrochloride liposomal doxorubicin |
| | 16 | | Gastrointestinal Agents | | Phase 4, Phase 3, Phase 1, Phase 2 | 8109 | | | | 17 | | Alkylating Agents | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 4694 | | | | 18 | | glucocorticoids | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 4920 | | | | 19 | | Hormone Antagonists | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 12778 | | | | 20 | | Dexamethasone acetate | | Phase 4, Phase 3, Phase 1, Phase 2 | 2084 | 1177-87-3 | | | 21 | | protease inhibitors | | Phase 4, Phase 3, Phase 1, Phase 2 | 5320 | | | | | 22 | | Topoisomerase Inhibitors | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 4945 | | | | 23 | | Peripheral Nervous System Agents | | Phase 4, Phase 3, Phase 1, Phase 2 | 22776 | | | | 24 | | Hormones, Hormone Substitutes, and Hormone Antagonists | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 12767 | | | | 25 | | Antifungal Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 3615 | | | | 26 | | Hormones | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 13979 | | | | 27 | | HIV Protease Inhibitors | | Phase 4, Phase 3, Phase 1, Phase 2 | 5319 | | | | 28 | | Etoposide phosphate | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 1232 | | | | 29 | | Angiogenesis Modulating Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 4072 | | | | 30 | | Anti-Bacterial Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 10884 | | | | 31 | | Antibiotics, Antitubercular | | Phase 4, Phase 3, Phase 2, Phase 1 | 6972 | | | | 32 | | Antiemetics | | Phase 4, Phase 3, Phase 1, Phase 2 | 3888 | | | | 33 | | Angiogenesis Inhibitors | | Phase 4, Phase 3, Phase 2, Phase 1 | 4143 | | | | 34 | | Dexamethasone 21-phosphate | | Phase 4, Phase 3, Phase 1, Phase 2 | 2084 | | | | 35 | | Antilymphocyte Serum | | Phase 4, Phase 2, Phase 3, Phase 1 | 399 | | | | 36 | | Antineoplastic Agents, Alkylating | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 4474 | | | | 37 | | Antirheumatic Agents | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 10627 | | | | 38 | | Anti-Infective Agents | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 21402 | | | | 39 | | Immunosuppressive Agents | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 12770 | | | | 40 | | Antiviral Agents | | Phase 4, Phase 3, Phase 1, Phase 2, Early Phase 1 | 9732 | | | | 41 | | Autonomic Agents | | Phase 4, Phase 3, Phase 1, Phase 2 | 9774 | | | | 42 | | BB 1101 | | Phase 4, Phase 3, Phase 1, Phase 2 | 2084 | | | | 43 | | Anti-Inflammatory Agents | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 10355 | | | | 44 | | Antineoplastic Agents, Phytogenic | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 5420 | | | | 45 | | Antimetabolites, Antineoplastic | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 7171 | | | | 46 | | Antineoplastic Agents, Hormonal | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 5407 | | | | 47 | | Antimitotic Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 5498 | | | | 48 | | Antimetabolites | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 11774 | | | | 49 | | Ketamine | approved, vet_approved | Phase 3 | 528 | 6740-88-1 | 3821 | (+-)-Ketamine (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone (+/-)-Ketamine (-)-Ketamine (S)-(-)-Ketamine (S)-Ketamine (±)-ketamine 100477-72-3 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone 2-(methylamino)-2-(2-chlorophenyl)cyclohexanone 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone 33643-45-7 6740-88-1 79499-51-7 AC1L1GSH AC1Q40UR AKOS001053247 BRN 2216965 C07525 C13H16ClNO CHEBI:138833 CHEBI:6121 CHEMBL742 CI 581 base CI-581 CID3821 CLSTA 20 Calypsol Cetamina Cetamina [INN-Spanish] Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI) Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI) Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI) D08098 DB01221 DEA No. 7285 | DL-ketamine DivK1c_000217 EINECS 229-804-1 Esketamine Green IDI1_000217 KBio1_000217 KETAMINE KETAMINE HCL Ketaject Ketalar Ketalar base Ketamina Ketamine (INN) Ketamine Base Ketamine HCL Ketamine [INN:BAN] Ketaminum Ketaminum [INN-Latin] Ketanest Ketoject Ketolar L-Ketamine LS-57301 MLS001331674 MolPort-001-838-070 NCGC00159480-02 NCGC00159480-03 NINDS_000217 NMDA NSC 70151 NSC70151 SMR000238141 Special K Special K [street name] Special k T385 Tekam Tekam (TN) UNII-690G0D6V8H dl-Ketamine ketamine l-Ketamine | |
| | 50 | | Lenalidomide | approved | Phase 3, Phase 1, Phase 2 | 718 | 191732-72-6 | 216326 | 1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline 191732-72-6 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione 346670-73-3 443912-14-9 AC-914 AC1L50II AKOS005146276 ALBB-015321 Bio-0168 C467567 CC 5013 CC-5013 CC-5013, Revlimid, Lenalidomide CC5013 CDC 501 CDC-501 CDC-5013 CHEMBL848 CID216326 Celgene brand of lenalidomide D04687 | DB00480 EC-000.2340 ENMD-0997 I06-0831 IMID-1 IMID-5013 IMiD3 IMiD3 cpd IMid-1 LS-184040 Lenalidomide Lenalidomide (USAN/INN) Lenalidomide [USAN] MolPort-003-848-370 NCGC00167491-01 NSC747972 Revamid Revimid Revlimid Revlimid (Celgene) Revlimid (TN) S1029_Selleck STK639603 Thalidomide analog CC-5013 UNII-F0P408N6V4 lenalidomide | |
|
Interventional clinical trials: (show top 50)
(show all 927)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | Completed | NCT00003398 | Phase 4 | | 2 | EDOCH Alternating With DHAP for New Diagnosed Younger MCL | Recruiting | NCT02858804 | Phase 4 | | 3 | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | Recruiting | NCT01180049 | Phase 4 | | 4 | An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | Active, not recruiting | NCT01833039 | Phase 4 | | 5 | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL | Unknown status | NCT00209209 | Phase 3 | | 6 | Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma | Unknown status | NCT00016887 | Phase 3 | | 7 | Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL | Unknown status | NCT01449344 | Phase 3 | | 8 | Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma | Unknown status | NCT00641095 | Phase 3 | | 9 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | Unknown status | NCT00209222 | Phase 3 | | 10 | Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma | Unknown status | NCT00003337 | Phase 3 | | 11 | Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | Unknown status | NCT00003338 | Phase 2, Phase 3 | | 12 | Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma | Unknown status | NCT00052936 | Phase 3 | | 13 | Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma | Unknown status | NCT00053768 | Phase 3 | | 14 | Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma | Unknown status | NCT00028717 | Phase 3 | | 15 | Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | Unknown status | NCT00002989 | Phase 3 | | 16 | Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia | Unknown status | NCT00020865 | Phase 3 | | 17 | Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia | Unknown status | NCT00445497 | Phase 3 | | 18 | Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain | Unknown status | NCT01316744 | Phase 3 | | 19 | Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma | Unknown status | NCT00003924 | Phase 3 | | 20 | Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease | Unknown status | NCT00002987 | Phase 3 | | 21 | Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma | Completed | NCT00003280 | Phase 3 | | 22 | Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) | Completed | NCT00117598 | Phase 3 | | 23 | Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) | Completed | NCT01073163 | Phase 3 | | 24 | Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab | Completed | NCT01456351 | Phase 3 | | 25 | Mantel Cell Lymphoma Efficacy of Rituximab Maintenance | Completed | NCT00921414 | Phase 3 | | 26 | Bendamustine Plus Rituximab Versus CHOP Plus Rituximab | Completed | NCT00991211 | Phase 3 | | 27 | A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma | Completed | NCT00269113 | Phase 3 | | 28 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | Completed | NCT00799461 | Phase 3 | | 29 | Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma | Completed | NCT00005590 | Phase 3 | | 30 | Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy | Completed | NCT00003341 | Phase 3 | | 31 | Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma | Completed | NCT00278421 | Phase 3 | | 32 | Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | Completed | NCT00278408 | Phase 3 | | 33 | Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count | Completed | NCT00003805 | Phase 3 | | 34 | St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer | Completed | NCT00005805 | Phase 3 | | 35 | Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter | Completed | NCT00006083 | Phase 3 | | 36 | Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer | Completed | NCT00661999 | Phase 3 | | 37 | Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer | Completed | NCT00070382 | Phase 3 | | 38 | Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial | Completed | NCT00750009 | Phase 3 | | 39 | American Ginseng in Treating Patients With Fatigue Caused by Cancer | Completed | NCT00719563 | Phase 3 | | 40 | Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain | Completed | NCT00666211 | Phase 3 | | 41 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma | Completed | NCT00004112 | Phase 3 | | 42 | Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients | Completed | NCT00003938 | Phase 3 | | 43 | Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment | Completed | NCT00008359 | Phase 3 | | 44 | Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain | Completed | NCT00538850 | Phase 3 | | 45 | Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer | Completed | NCT00265837 | Phase 3 | | 46 | Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation | Completed | NCT00014391 | Phase 3 | | 47 | Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation | Completed | NCT00003883 | Phase 3 | | 48 | Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant | Completed | NCT00305851 | Phase 3 | | 49 | Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation | Completed | NCT00004230 | Phase 3 | | 50 | Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation | Completed | NCT00045292 | Phase 3 |
Cell-based therapeutics:Data from LifeMap, the Embryonic Development and Stem Cells Database Stem-cell-based therapeutic approaches for Mantle Cell Lymphoma: Embryonic/Adult Cultured Cells Related to Mantle Cell Lymphoma:
|
